{
  "study_overview": {
    "title": "Medications for Opioid Use Disorder (MOUD) Study",
    "description": "CDC National Center for Injury Prevention and Control longitudinal study tracking treatment outcomes for opioid use disorder across the United States",
    "total_patients": 1974,
    "study_period": {
      "start_date": "March 2018",
      "end_date": "May 2021",
      "duration": "3+ years",
      "follow_up_period": "18 months per patient"
    },
    "timepoints": {
      "baseline": {
        "label": "Baseline",
        "description": "Treatment initiation (March 2018 onwards)"
      },
      "3_month": {
        "label": "3-Month Follow-up",
        "description": "3 months post-baseline"
      },
      "6_month": {
        "label": "6-Month Follow-up",
        "description": "6 months post-baseline"
      },
      "12_month": {
        "label": "12-Month Follow-up",
        "description": "12 months post-baseline"
      },
      "18_month": {
        "label": "18-Month Follow-up",
        "description": "18 months post-baseline (May 2021)"
      }
    },
    "study_locations": [
      "Birmingham, AL",
      "Boston, MA",
      "Chicago, IL",
      "Cincinnati, OH",
      "Dallas, TX",
      "Denver, CO",
      "Huntington, WV",
      "Los Angeles, CA",
      "New York, NY",
      "Phoenix, AZ",
      "Raleigh-Durham, NC",
      "Salt Lake City, UT",
      "San Francisco, CA",
      "Seattle, WA",
      "Washington, DC Metro Area"
    ],
    "data_collection_period": "18 months per patient",
    "response_rates": {
      "baseline": "100% (1,974 patients)",
      "3_month": "72%",
      "6_month": "68%",
      "12_month": "52%",
      "18_month": "53%"
    }
  },
  "treatment_outcomes": {
    "baseline": {
      "timepoint": "baseline",
      "total_patients": 1974,
      "buprenorphine": 651,
      "methadone": 1224,
      "naltrexone": 86,
      "opioid_use_30_days": 50,
      "bup_rate": 33.0,
      "mmt_rate": 62.0,
      "ntx_rate": 4.4,
      "opioid_rate": 2.5
    },
    "3_month": {
      "timepoint": "3_month",
      "total_patients": 1974,
      "buprenorphine": 386,
      "methadone": 871,
      "naltrexone": 26,
      "opioid_use_30_days": 6,
      "bup_rate": 19.6,
      "mmt_rate": 44.1,
      "ntx_rate": 1.3,
      "opioid_rate": 0.3
    },
    "6_month": {
      "timepoint": "6_month",
      "total_patients": 1974,
      "buprenorphine": 321,
      "methadone": 782,
      "naltrexone": 16,
      "opioid_use_30_days": 8,
      "bup_rate": 16.3,
      "mmt_rate": 39.6,
      "ntx_rate": 0.8,
      "opioid_rate": 0.4
    },
    "12_month": {
      "timepoint": "12_month",
      "total_patients": 1974,
      "buprenorphine": 281,
      "methadone": 596,
      "naltrexone": 35,
      "opioid_use_30_days": 3,
      "bup_rate": 14.2,
      "mmt_rate": 30.2,
      "ntx_rate": 1.8,
      "opioid_rate": 0.2
    },
    "18_month": {
      "timepoint": "18_month",
      "total_patients": 1974,
      "buprenorphine": 280,
      "methadone": 590,
      "naltrexone": 35,
      "opioid_use_30_days": 6,
      "bup_rate": 14.2,
      "mmt_rate": 29.9,
      "ntx_rate": 1.8,
      "opioid_rate": 0.3
    }
  },
  "demographics": {
    "total_patients": 1974,
    "sex": {
      "Female": 1062,
      "Male": 912
    },
    "age_categories": {
      "46-55": 374,
      "26-35": 651,
      "36-45": 574,
      "56-65": 255,
      "18-25": 120
    },
    "race_ethnicity": {
      "Black/African American": 1337,
      "Asian": 319,
      "White": 196,
      "Hispanic/Latino": 122
    },
    "education": {
      "Less than High School": 406,
      "High School/GED": 694,
      "Some College": 874
    },
    "employment": {
      "Status 0": 1425,
      "Full-time": 549
    }
  },
  "healthcare_utilization": {
    "baseline": {
      "timepoint": "baseline",
      "total_patients": 1974,
      "avg_ed_visits": 0.14,
      "avg_hospital_stays": 0,
      "patients_with_ed_visits": 569,
      "patients_with_hospital_stays": 0
    },
    "3_month": {
      "timepoint": "3_month",
      "total_patients": 1974,
      "avg_ed_visits": 0.1,
      "avg_hospital_stays": 0,
      "patients_with_ed_visits": 280,
      "patients_with_hospital_stays": 0
    },
    "6_month": {
      "timepoint": "6_month",
      "total_patients": 1974,
      "avg_ed_visits": 0.11,
      "avg_hospital_stays": 0,
      "patients_with_ed_visits": 298,
      "patients_with_hospital_stays": 0
    },
    "12_month": {
      "timepoint": "12_month",
      "total_patients": 1974,
      "avg_ed_visits": 0.08,
      "avg_hospital_stays": 0,
      "patients_with_ed_visits": 174,
      "patients_with_hospital_stays": 0
    },
    "18_month": {
      "timepoint": "18_month",
      "total_patients": 1974,
      "avg_ed_visits": 0.1,
      "avg_hospital_stays": 0,
      "patients_with_ed_visits": 211,
      "patients_with_hospital_stays": 0
    }
  },
  "moud_medications": {
    "buprenorphine": {
      "name": "Buprenorphine",
      "description": "Partial opioid agonist that reduces cravings and withdrawal symptoms",
      "brand_names": [
        "Suboxone",
        "Subutex",
        "Zubsolv"
      ]
    },
    "methadone": {
      "name": "Methadone",
      "description": "Full opioid agonist administered in specialized clinics",
      "brand_names": [
        "Dolophine",
        "Methadose"
      ]
    },
    "naltrexone": {
      "name": "Naltrexone",
      "description": "Opioid antagonist that blocks the effects of opioids",
      "brand_names": [
        "Vivitrol",
        "ReVia",
        "Depade"
      ]
    }
  }
}